- Home
- SRTS vs ALGS Comparison
SRTS vs ALGS Comparison
Compare SRTS & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- ALGS
- Stock Information
- Founded
- SRTS 2010
- ALGS 2018
- Country
- SRTS United States
- ALGS United States
- Employees
- SRTS N/A
- ALGS N/A
- Industry
- SRTS Medical/Dental Instruments
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- SRTS Health Care
- ALGS Health Care
- Exchange
- SRTS Nasdaq
- ALGS Nasdaq
- Market Cap
- SRTS 51.8M
- ALGS 53.0M
- IPO Year
- SRTS 2016
- ALGS 2020
- Fundamental
- Price
- SRTS $3.15
- ALGS $9.99
- Analyst Decision
- SRTS Strong Buy
- ALGS Strong Buy
- Analyst Count
- SRTS 3
- ALGS 2
- Target Price
- SRTS $8.00
- ALGS $60.00
- AVG Volume (30 Days)
- SRTS 84.7K
- ALGS 71.7K
- Earning Date
- SRTS 11-13-2025
- ALGS 11-05-2025
- Dividend Yield
- SRTS N/A
- ALGS N/A
- EPS Growth
- SRTS N/A
- ALGS N/A
- EPS
- SRTS N/A
- ALGS N/A
- Revenue
- SRTS $37,564,000.00
- ALGS $3,174,000.00
- Revenue This Year
- SRTS N/A
- ALGS N/A
- Revenue Next Year
- SRTS $46.14
- ALGS $28.79
- P/E Ratio
- SRTS N/A
- ALGS N/A
- Revenue Growth
- SRTS 3.29
- ALGS N/A
- 52 Week Low
- SRTS $3.03
- ALGS $3.76
- 52 Week High
- SRTS $9.33
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- SRTS 37.43
- ALGS 51.70
- Support Level
- SRTS $3.09
- ALGS $8.90
- Resistance Level
- SRTS $3.29
- ALGS $11.65
- Average True Range (ATR)
- SRTS 0.11
- ALGS 0.76
- MACD
- SRTS 0.04
- ALGS -0.25
- Stochastic Oscillator
- SRTS 15.38
- ALGS 39.64
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.